Evidence map›Paper›PMID 34266934›Full record

ArticleInternational journal of spine surgery2021

Final Long-Term Reporting from a Randomized Controlled IDE Trial for Lumbar Artificial Discs in Single-Level Degenerative Disc Disease: 7-Year Results.

Kris Radcliff, Jack Zigler, Ernest Braxton, Glen Buttermann, Dom Coric, Peter Derman, Rolando Garcia, Anton Jorgensen, Nicole C Ferko, Aaron Situ and 1 more

Erratum issuedOpen access · diamondAbstract read
In one paragraph

Article in International journal of spine surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. The Decline of Lumbar Artificial Disc Replacement.Journal of spine research and surgery · 2024
    Article
  5. Article
  6. Usefulness of Detecting Brain-Derived Neurotrophic Factor in Intervertebral Disc Degeneration of the Lumbosacral Spine.Medical science monitor : international medical journal of experimental and clinical research · 2023
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Kris RadcliffRothman Orthopedic Institute, Philadelphia, Pennsylvania.
Jack ZiglerTexas Back Institute, Plano, Texas.
Ernest BraxtonVail Health Vail Summit Orthopaedics and Neurosurgery, Vail, Colorado.
Glen ButtermannMidwest Spine & Brain Institute, Stillwater, Minnesota.
Dom CoricCarolina Neurosurgery and Spine Associates, Charlotte, North Carolina.
Peter DermanTexas Back Institute, Plano, Texas.
Rolando GarciaOrthopedic Care Center, Aventura, Florida.
Anton JorgensenOrtho San Antonio, San Antonio, Texas.
Nicole C FerkoCRG-EVERSANA Canada, Inc, Burlington, Ontario, Canada.
Aaron SituCRG-EVERSANA Canada, Inc, Burlington, Ontario, Canada.
James YueFrank H. Netter School of Medicine, Quinnipiac University, Hamden, Connecticut.
EVERSANA (Canada) · CATexas Back Institute · USAventura Hospital and Medical Center · USCarolina Neurosurgery and Spine Associates · USOrthopedic Institute · USQuinnipiac University · USUrology San Antonio · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study compared 7-year safety and efficacy outcomes of activL and ProDisc-L lumbar total disc replacements in patients with symptomatic, single-level lumbar degenerative disc disease (DDD). The objectives are to report 7-year outcomes of the trial, evaluate the outcomes for patients lost to follow-up, and determine whether early outcomes predict long-term outcomes.

methodsThis was a prospective, multicenter, randomized, controlled investigational device exemption study. Eligible patients with symptomatic, single-level lumbar DDD had failed ≥6 months of nonsurgical management. Patients (

resultsAt 7 years, the activL group was noninferior to the ProDisc-L group on the primary composite endpoint (

conclusionsThe benefits of activL and ProDisc-L are maintained after 7 years, with significant improvements from baseline observed in pain, function, and opioid use. activL is more effective at preserving ROM than ProDisc-L and has a more favorable safety profile. Improvements in other primary and secondary outcomes were similar between both disc designs. LEVEL OF EVIDENCE: 1.

Indexed as

activLartificial discback paindegenerative disc diseasemotion preservationtotal disc replacement

Identifiers

PMID34266934
PMCPMC8375685
OpenAlexW3182770497

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.